INS and Insulin resistance: When combined with hypoglycemic drugs, BBR significantly improved FPG (MD = −0.99 mmol/L, p < 0.01), 2hPBG (MD = −1.07 mmol/L, p < 0.01), glycated hemoglobin (HbA1c) (MD = −0.69%, p < 0.01), and other metabolic markers, including fasting insulin (Fins), homeostasis model assessment index for assessing insulin resistance (HOMA-IR), lipid profiles and inflammatory markers.